Healthcare entity
American Society of Clinical Oncology (ASCO) is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Source depth averages 2.5 original sources per story, versus 5 across the same-window beat baseline. The 123-day window averages about 0.1 stories each week.
Last mentioned: Jul 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
American Society of Clinical Oncology (ASCO) is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Source depth averages 2.5 original sources per story, versus 5 across the same-window beat baseline. The 123-day window averages about 0.1 stories each week. The 6 average consequence score is below the beat benchmark of 6.4 in the same window. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. This profile follows 2 Healthcare stories mentioning Grail across the period from March 22, 2026 to July 22, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 287 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Grail. Shared-story counts are live from our verified record — not editorial picks.
Global Milestone Announcement
Gene Solutions issues press release detailing ASCO recognition, FDA designation, and IPO plans, marking a turning point for the company.
FDA Breakthrough Device Designation
The U.S. FDA grants Breakthrough Device Designation to SPOT-MAS 10, acknowledging its potential to address unmet needs in cancer screening.
ASCO Breakthrough 2026
Gene Solutions presents interim real-world data from 84,145 asymptomatic individuals for SPOT-MAS 10 at the ASCO Breakthrough conference in Singapore.
Market Outperformance
Grail shares end the week as a top performer in the healthcare sector, recouping major losses.
TD Cowen Upgrade
TD Cowen upgrades Grail to 'Buy,' arguing the market overreacted to the leadership change.
CEO Transition & Setback
CEO Bob Ragusa retires following reports of a clinical trial setback, causing a sharp drop in GRAL shares.
A massive real-world study and FDA Breakthrough Device Designation position SPOT-MAS 10 as a potential paradigm shift in multi-cancer screening across Asian healthcare systems, offering a non-invasive, population-validated tool to combat rising cancer burdens.
Source: thehindubusinessline.com · thehindu.com
Grail (GRAL) stock staged a major recovery this week, outperforming the broader market after a pivotal upgrade from TD Cowen. The rally marks a significant shift in investor sentiment following a volatile period triggered by a CEO transition and clinical trial concerns.
Source: finance.yahoo.com · fool.com
Grail is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
